Monitor upcoming FDA feedback and trial design announcement in Q2 2026, which could catalyze the stock despite the minor EPS miss. CFO transition may introduce short-term uncertainty but does not affect cash runway or development timeline.
Price Chart
Executive Summary
Fulcrum Therapeutics reported a net loss of $18.9 million for Q1 2026 with EPS of $-0.25, narrowly missing consensus EPS of $-0.30 by 3.1%. The company highlighted positive clinical data for pociredir in sickle cell disease and extended its cash runway into 2029, but CFO Alan Musso announced retirement.
Key Financial Metrics
Key Facts
- EPS was $-0.25 for Q1 2026, missing consensus of $-0.30 by 3.1% (slight miss)
- Revenue remained $0 as expected for this clinical-stage biopharma
- Cash, cash equivalents, and marketable securities totaled $333.3 million as of March 31, 2026, down from $352.3 million at year-end
- Cash runway now extends into 2029, providing long-term funding for development of pociredir
- Positive clinical data from the PIONEER trial showed robust HbF induction and improvements in hemolysis and anemia in sickle cell patients
- Plans to initiate a potential registration-enabling trial in second half of 2026 pending FDA feedback
- CFO Alan Musso to retire later this year; search for successor underway
Financial Impact
Minimal near-term financial impact; operating loss increased slightly to $18.9M from $17.7M YoY. Cash burn of $19M in the quarter supports ongoing trials.
Risk Factors
- CFO retirement could create leadership gap during critical development phase
- Clinical development risk ahead of registrational trial initiation
- Dilution risk if future capital raises are needed beyond 2029
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3281455 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | S-4 | $3.85 $3.70 | ▲ +3.90% | ▲ +3.57% | $3.67 (+4.68%) |
Aug 17, 2026 6w ago | 425 | $3.84 $3.78 | ▲ +1.56% | ▼ −0.42% | $3.67 (+4.43%) |
Aug 17, 2026 6w ago | 425 | $3.84 $3.78 | ▼ −1.56% | ▲ +0.42% | $3.67 (−4.43%) |
Aug 17, 2026 6w ago | 8-K | $3.84 $3.78 | ▼ −1.56% | ▲ +0.42% | $3.67 (−4.43%) |
Aug 17, 2026 6w ago | Press Release | $3.84 $3.78 | ▼ −1.56% | ▲ +0.42% | $3.67 (−4.43%) |
Aug 10, 2026 7w ago | 8-K | $3.75 $3.82 | ▲ +1.87% | ▲ +2.78% | $3.67 (−2.13%) |
Jul 15, 2026 11w ago | 3 | $3.50 $3.71 | ▲ +6.00% | ▲ +2.38% | $3.67 (+4.86%) |
Jun 11, 2026 16w ago | Institutional Cluster | $3.55 $3.59 | ▲ +1.13% | ▼ −0.76% | $3.67 (+3.38%) |
Apr 27, 2026 22w ago | 8-K | $7.72 $6.76 | ▼ −12.44% | ▼ −17.39% | $3.67 (−52.46%) |
Apr 27, 2026 22w ago | Press Release | $7.72 $6.76 | ▼ −12.44% | ▼ −17.39% | $3.67 (−52.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access